Abstract
Restless legs syndrome (RLS) is a common and clinically significant motor disorder increasingly recognized by physicians and the general public, yet still underdiagnosed, underreported, and undertreated. Effective therapies are available, but a high index of suspicion is required to make the diagnosis and start treatment quickly. We now have enough data to support the use of dopaminergic agents, benzodiazepines, antiepileptics, and opioids in these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 769-787 |
| Number of pages | 19 |
| Journal | Cleveland Clinic Journal of Medicine |
| Volume | 72 |
| Issue number | 9 |
| State | Published - Sep 1 2005 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Restless legs syndrome : Keys to recognition and treatment. / Avecillas, Jaime F.; Golish, Joseph A.; Giannini, Carmen; Yataco, José C.
In: Cleveland Clinic Journal of Medicine, Vol. 72, No. 9, 01.09.2005, p. 769-787.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Restless legs syndrome
T2 - Keys to recognition and treatment
AU - Avecillas, Jaime F.
AU - Golish, Joseph A.
AU - Giannini, Carmen
AU - Yataco, José C.
PY - 2005/9/1
Y1 - 2005/9/1
N2 - Restless legs syndrome (RLS) is a common and clinically significant motor disorder increasingly recognized by physicians and the general public, yet still underdiagnosed, underreported, and undertreated. Effective therapies are available, but a high index of suspicion is required to make the diagnosis and start treatment quickly. We now have enough data to support the use of dopaminergic agents, benzodiazepines, antiepileptics, and opioids in these patients.
AB - Restless legs syndrome (RLS) is a common and clinically significant motor disorder increasingly recognized by physicians and the general public, yet still underdiagnosed, underreported, and undertreated. Effective therapies are available, but a high index of suspicion is required to make the diagnosis and start treatment quickly. We now have enough data to support the use of dopaminergic agents, benzodiazepines, antiepileptics, and opioids in these patients.
UR - http://www.scopus.com/inward/record.url?scp=25844523301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=25844523301&partnerID=8YFLogxK
M3 - Article
C2 - 16193825
AN - SCOPUS:25844523301
VL - 72
SP - 769
EP - 787
JO - Cleveland Clinic Journal of Medicine
JF - Cleveland Clinic Journal of Medicine
SN - 0891-1150
IS - 9
ER -